中文 | English
Return
Total: 423 , 1/43
Show Home Prev Next End page: GO
Author:(Mi WU)

1.Factors affecting benefit finding among young and middle-aged patients with type 2 diabetes mellitus

WU Chenghui ; PENG Yanhong ; ZHANG Ke ; ZHU Weiye ; DENG Liang ; TAN Lingling ; QU Dandan ; MI Qiuxiang

Journal of Preventive Medicine 2026;38(1):31-35

2.Treatment Principles and Paradigm of Diabetic Microvascular Complications Responding Specifically to Traditional Chinese Medicine

Anzhu WANG ; Xing HANG ; Lili ZHANG ; Xiaorong ZHU ; Dantao PENG ; Ying FAN ; Min ZHANG ; Wenliang LYU ; Guoliang ZHANG ; Xiai WU ; Jia MI ; Jiaxing TIAN ; Wei ZHANG ; Han WANG ; Yuan XU ; .LI PINGPING ; Zhenyu WANG ; Ying ZHANG ; Dongmei SUN ; Yi HE ; Mei MO ; Xiaoxiao ZHANG ; Linhua ZHAO

Chinese Journal of Experimental Traditional Medical Formulae 2026;32(5):272-279

3.Residual cell types,molecular expression profiles and quality assessment of in vitro cultured human thymic slices

Wanqing GUAN ; Guihua LUO ; Jingxuan HAN ; Qun XIANG ; Yunfei AN ; Lu ZHAO ; Jianhong MI ; Zeqing FENG ; Yuzhang WU

Journal of Army Medical University 2025;47(9):893-903

4.Best evidence summary for diaphragm rehabilitation in ICU patients with mechanical ventilation

Dong XIANG ; Yuanyuan MI ; Wei WU ; Xiaojie WU ; Zhuoya ZHANG ; Jun LEI ; Yuanting HE ; Haiyan HUANG

Chongqing Medicine 2025;54(7):1679-1685,1692

5.Natural polyphenols as novel interventions for aging and age-related diseases: Exploring efficacy, mechanisms of action and implications for future research.

Wenze WU ; Yan MI ; Qingqi MENG ; Ning LI ; Wei LI ; Pu WANG ; Yue HOU

Chinese Herbal Medicines 2025;17(2):279-291

6.Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor

Huaxin ZHAO ; Yanling WU ; Soo Mi KIM

The Korean Journal of Physiology and Pharmacology 2025;29(3):321-335

7.Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor

Huaxin ZHAO ; Yanling WU ; Soo Mi KIM

The Korean Journal of Physiology and Pharmacology 2025;29(3):321-335

8.Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor

Huaxin ZHAO ; Yanling WU ; Soo Mi KIM

The Korean Journal of Physiology and Pharmacology 2025;29(3):321-335

9.Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor

Huaxin ZHAO ; Yanling WU ; Soo Mi KIM

The Korean Journal of Physiology and Pharmacology 2025;29(3):321-335

10.Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor

Huaxin ZHAO ; Yanling WU ; Soo Mi KIM

The Korean Journal of Physiology and Pharmacology 2025;29(3):321-335

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 423 , 1/43 Show Home Prev Next End page: GO